In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Novo Nordisk to test next gen obesity drug CagriSema in children Reuters ADA 2025: CagriSema Demonstrates Significant Weight Loss in REDEFINE Clinical Trials Pharmacy Times Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library